These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 15497674)

  • 1. Novel approaches to vaccine delivery.
    O'Hagan DT; Rappuoli R
    Pharm Res; 2004 Sep; 21(9):1519-30. PubMed ID: 15497674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel approaches to pediatric vaccine delivery.
    O'Hagan DT; Rappuoli R
    Adv Drug Deliv Rev; 2006 Apr; 58(1):29-51. PubMed ID: 16480788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccines: An Important Tool for Infectious Disease.
    Saman S; Chauhan I; Srivastava N
    Recent Adv Antiinfect Drug Discov; 2023; 18(2):88-109. PubMed ID: 36380412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Needle-free vaccine delivery.
    Giudice EL; Campbell JD
    Adv Drug Deliv Rev; 2006 Apr; 58(1):68-89. PubMed ID: 16564111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal delivery of vaccine antigens and its advantages in pediatrics.
    De Magistris MT
    Adv Drug Deliv Rev; 2006 Apr; 58(1):52-67. PubMed ID: 16516335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational application of nanoadjuvant for mucosal vaccine delivery system.
    Dewangan HK
    J Immunol Methods; 2020; 481-482():112791. PubMed ID: 32387695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioadhesive delivery systems for mucosal vaccine delivery.
    Baudner BC; O'Hagan DT
    J Drug Target; 2010 Dec; 18(10):752-70. PubMed ID: 21039314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel antigen delivery technologies: a review.
    Jain D; Jain V; Singh R
    Drug Deliv Transl Res; 2011 Apr; 1(2):103-12. PubMed ID: 25788109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulators and delivery systems for vaccination by mucosal routes.
    Ryan EJ; Daly LM; Mills KH
    Trends Biotechnol; 2001 Aug; 19(8):293-304. PubMed ID: 11451471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine delivery--current trends and future.
    Azad N; Rojanasakul Y
    Curr Drug Deliv; 2006 Apr; 3(2):137-46. PubMed ID: 16611000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.
    Vajdy M; Srivastava I; Polo J; Donnelly J; O'Hagan D; Singh M
    Immunol Cell Biol; 2004 Dec; 82(6):617-27. PubMed ID: 15550120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal adjuvants.
    Harandi AM; Medaglini D
    Curr HIV Res; 2010 Jun; 8(4):330-5. PubMed ID: 20353395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology solutions for mucosal immunization.
    Chadwick S; Kriegel C; Amiji M
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanocarriers for systemic and mucosal vaccine delivery.
    Shahiwala A; Vyas TK; Amiji MM
    Recent Pat Drug Deliv Formul; 2007; 1(1):1-9. PubMed ID: 19075870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccine adjuvants: key tools for innovative vaccine design.
    Riese P; Schulze K; Ebensen T; Prochnow B; Guzmán CA
    Curr Top Med Chem; 2013; 13(20):2562-80. PubMed ID: 24066891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strategies for mucosal vaccine development.
    Boyaka PN; Marinaro M; Vancott JL; Takahashi I; Fujihashi K; Yamamoto M; van Ginkel FW; Jackson RJ; Kiyono H; McGhee JR
    Am J Trop Med Hyg; 1999 Apr; 60(4 Suppl):35-45. PubMed ID: 10344675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.
    Wang X; Wang N; Li N; Zhen Y; Wang T
    Hum Vaccin Immunother; 2016 Aug; 12(8):2075-2089. PubMed ID: 27159879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous vaccines: novel advances in technology and delivery for overcoming the barriers.
    Li N; Peng LH; Chen X; Nakagawa S; Gao JQ
    Vaccine; 2011 Aug; 29(37):6179-90. PubMed ID: 21740946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "IDEAL" vaccines for resource poor settings.
    Levine MM
    Vaccine; 2011 Dec; 29 Suppl 4():D116-25. PubMed ID: 22486974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in vaccine adjuvants for systemic and mucosal administration.
    O'Hagan DT
    J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.